Industrial applicability for purified paratuberculin veterinary grade API is restricted to parenteral diagnostic and in vitro assay systems. Tablets, capsules, granules, and feed premixes are not established or technically rational finished dosage forms for this heat-labile protein antigen; no validated oral absorption pathway exists for a diagnostic antigen, and no pharmacopoeial monograph supports tableting or encapsulation of this material. The application routes below therefore cover injectable solutions, lyophilised powders for reconstitution, and liquid assay reagents only.

Manufacture of injectable intradermal test solutions from purified paratuberculin API is carried out in a closed stainless-steel mixing stream where the concentrated antigen stock is first chilled to 2–8°C and then diluted into sterile phosphate-buffered saline containing 0.5% phenol as preservative. The working antigen strength is standardised to 1.0 mg protein nitrogen per mL, with traceability to a reference lot whose potency was assigned in sensitised guinea pig assays; the administered dosage in cattle is 0.1 mL by intradermal injection at the caudal fold or mid-cervical site. Sterile filtration is performed through a 0.22 µm PVDF cartridge under nitrogen pressure at 0.5–1.0 bar, and the filtrate is collected into depyrogenated Type I borosilicate vials. Filling occurs in an EU GMP Annex 1 Grade A environment supported by an ISO 14644-1:2015 Class 5 background, and batch release includes sterility testing according to Ph. Eur. 2.6.1, bacterial endotoxin testing according to Ph. Eur. 2.6.14 with a limit of <5 IU per 0.1 mL dose, and preservative content verification by reversed-phase HPLC. Terminal product types include 5 mL, 10 mL, and 20 mL multi-dose vials labelled for veterinary diagnostic use; readout is performed at 72 ± 4 h and interpreted against a paired avian PPD negative control. A known operational boundary is that the diluted solution aggregates above pH 7.8 and after more than three freeze-thaw cycles, so the filling line must maintain 2–8°C continuously and the API concentrate must never be exposed to room temperature during media preparation.

What Limits Paratuberculin Antigen Stability in Whole-Blood IGRA Stimulation Panels?

Whole-blood IGRA stimulation panels supplied to regional veterinary diagnostic laboratories are prepared by adding purified paratuberculin antigen to heparinised blood within 30 minutes of venepuncture. The standard addition ratio is 20 µg protein per 1 mL of whole blood, diluted from a 1.0 mg/mL stock using RPMI 1640 without phenol red; a 1:50 dilution is prepared under laminar flow and used immediately because preservative-free working dilutions lose measurable stimulatory activity after 4 h at 2–8°C. Incubation is performed in a humidified 5% CO₂ atmosphere at 37°C for 20–24 h; plasma is harvested by centrifugation at 300 × g for 10 minutes and tested in an M. avium subsp. paratuberculosis IFN-γ ELISA. The method is aligned with the WOAH Terrestrial Manual chapter on paratuberculosis, and testing laboratories operate under ISO 15189:2022; where the antigen is supplied as a bulk diagnostic kit reagent, U.S. importers reference USDA Center for Veterinary Biologics guidance for diagnostic kit reagents. A critical process conflict is preservative compatibility: phenol concentrations above 0.1% in the stimulation tube depress IFN-γ secretion, but the absence of phenol reduces the multi-dose shelf life of the working dilution to <8 h. Terminal products are single-use 1.5 mL stimulation tubes, 96-well culture plates with soluble stimulation formats, and cryovials of lyophilised stimulation control shipped at 2–8°C. Published data for lot-specific IFN-γ responses in non-bovine species is limited; therefore each master lot must be titrated in a panel of five M. avium-sensitised cattle to establish the appropriate protein nitrogen range before release.

Lyophilized Antigen Powders for Plate-Coating and Serum Panel Assembly

Powdered purified paratuberculin for ELISA plate coating is produced by formulating the sterile-filtered API concentrate with stabilisers at an excipient-to-API ratio of 9:1 (w/w), using trehalose dihydrate and mannitol in a 70:30 mass ratio. The formulated bulk is aseptically filled at 1.0 mL per 2 mL amber glass vial, loaded onto stainless-steel lyophiliser shelves, frozen at −40°C for 4 h, and dried with a primary shelf temperature of −20°C and a secondary temperature ramp to +20°C over 48 h at a chamber pressure of 80–100 µbar. Residual moisture is controlled by USP <921> Method Ia Karl Fischer titration at <1.0% w/w, and cake appearance is recorded for re-dissolution after reconstitution in 1.0 mL of 0.01 M phosphate buffer pH 7.4. The reconstituted antigen is diluted in carbonate-bicarbonate coating buffer pH 9.6 to a final coating concentration of 5 µg protein per well in 100 µL volume, with overnight incubation at 2–8°C. Compliance for in vitro diagnostic kit manufacturing includes ISO 13485:2016 for quality management, Ph. Eur. 2.6.7 for mycoplasma testing, USP <71> for sterility of the aseptically processed powder, and ISO 14644-1:2015 Class 7 for pre-fill formulation steps. Terminal product types are 96-well ELISA plates for serum antibody detection, bulk lyophilised antigen vials for dairy herd milk ELISA panels, and desiccated antigen-coated strips for regional Johne’s disease screening programmes. Operationally, the powder is hygroscopic above 60% relative humidity and must be handled under dry nitrogen; loss of cake structure after reconstitution is a batch rejection indicator even if sterility remains acceptable.

Reference materials for inter-laboratory potency and plate-coating consistency are prepared from the same purified paratuberculin API stock by aseptic dilution into Dulbecco’s phosphate-buffered saline containing 0.5% bovine serum albumin and 0.1% sodium azide to a final protein nitrogen concentration of 2.0 mg/mL. The azide-containing solution is restricted to in vitro calibration use and must not be applied to intradermal injection or whole-blood culture. Aliquoting is performed into sterile 0.5 mL screw-cap cryovials under a nitrogen overlay, with 0.25 mL per vial, followed by snap-freezing in vapour-phase liquid nitrogen and transfer to −80°C freezers with continuous temperature logging. Compliance is maintained under ISO/IEC 17025:2017 for analytical laboratory operations and ISO 17034:2016 for reference material producer competence. Each fill lot is assigned a relative potency value by ELISA against a frozen master reference; the acceptance interval is 90–110% relative potency. Terminal products are freeze-stable reference panels used to calibrate plate-coating antigen lots, verify intradermal reagent potency during stability monitoring, and grade proficiency testing samples distributed to veterinary diagnostic networks. Batch-to-batch variance in carrier protein quality can shift the ELISA signal when bovine serum albumin from different suppliers is used, so the carrier protein source must be fixed by certificate of analysis after each supplier audit.

When Cold-Chain Dilution Networks Rely on Repeatable Sterile Filtration

In high-throughput national control programmes, a central facility often receives paratuberculin concentrate and prepares multiple working dilutions for intradermal use and IGRA. The concentrate is first brought to 2–8°C, then passed through a 0.22 µm polyethersulfone capsule filter at a flow rate of 50–100 mL/min into sterile polypropylene containers; the diluent for intradermal application is phosphate-buffered saline with 0.5% phenol and 0.01% polysorbate 20, and the final protein nitrogen concentration is adjusted to 1.0 mg/mL. For IGRA dilution, the same sterile-filtered intermediate is mixed 1:50 with RPMI 1640 medium without phenol red and distributed into preservative-free single-use tubes within a Grade A isolator. Records include filter integrity test results, diluted batch pH at 7.2–7.4, bioburden counts before filtration, and cold-chain logger data for every shipment segment. Compliance references ISO 15189:2022 for medical laboratory quality, ISO 22367:2020 for risk management in laboratory processes, and national accreditation requirements for diagnostic reagent dispensing. Terminal product types are ready-to-use intradermal vials, 1.5 mL IGRA stimulation tubes, and labelled sub-batch containers for distribution to satellite laboratories. An important operational limit is that if polysorbate 20 concentration exceeds 0.05%, the diluent must be revalidated for skin test reactivity because published data for this specific configuration is limited.

Coupling of purified paratuberculin to carboxylated magnetic microspheres supports multiplex serology panels for bovine enteric disease monitoring. The antigen is buffer-exchanged into 50 mM 2-(N-morpholino)ethanesulfonic acid pH 5.0, then covalently conjugated to 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-activated microspheres at a loading ratio of 20 µg protein per 1 × 10⁶ beads. After 2 h of rotary incubation at ambient temperature, unreacted carboxyl groups are blocked with 1% ethanolamine in phosphate-buffered saline for 30 minutes, and the conjugated beads are stored in a stabilising buffer containing 0.1% bovine serum albumin and 0.05% sodium azide at 2–8°C. The manufacturing process must follow ISO 13485:2016, and the conjugation steps are controlled by bead count and median fluorescence intensity on a flow cytometer calibrated to the vendor’s calibration microspheres. Addition ratio can be varied from 5 µg to 40 µg per 1 × 10⁶ beads for panel optimisation; lower loadings reduce assay background while higher loadings improve detection of weak antibody responses. Terminal product types are multiplex bead sets for bovine pathogen antibody profiling, custom magnetic bead vials for research-use-only assay development, and OEM bead packs supplied to contract diagnostic platforms. An operational boundary is that the conjugated beads aggregate irreversibly when frozen without cryoprotectant, so shipping is restricted to liquid buffer at 2–8°C. Published data for conjugated paratuberculin stability beyond 12 months is limited; accelerated stability studies at 37°C are used for batch release only with real-time 2–8°C confirmation.